Anne M Mazzola

Plain English
This study looked at a patient with chronic watery diarrhea caused by two gut infections: intestinal spirochaetosis and Giardia lamblia. The patient displayed symptoms that could be confused with other serious conditions, which delayed their correct diagnosis and treatment. After being treated with metronidazole, the patient's symptoms improved, and the infections were completely cleared. Who this helps: This research benefits doctors by guiding them on how to better diagnose and treat patients with similar symptoms.

Plain English
This study looked at nearly 10,000 patients to understand Autoimmune Polyglandular Syndrome (APS), finding that about 1 in 8 had this condition. Of these patients, those diagnosed during their first visit had a different mix of male and female patients compared to those diagnosed later, and half developed the syndrome within about 8 years. The results highlight the importance of specialized follow-up and recommend routine reproductive health checks, especially since there's a significant risk of early ovarian failure. Who this helps: This helps patients with APS and the doctors who treat them.

Plain English
This study looked at how well tofacitinib, a medication for ulcerative colitis (UC), worked in patients who did not respond to previous treatments with anti-TNF drugs. Out of 58 patients, only 6 (10.3%) needed surgery to remove their colon, and many showed improvement in their symptoms after 52 weeks: 53.4% achieved clinical remission, and 50% showed improvement in their colon's condition during follow-up checks. These results are important because they suggest tofacitinib can effectively help patients avoid surgery and manage their UC symptoms. Who this helps: This helps patients with ulcerative colitis who have not responded to anti-TNF treatments.

Plain English
This study looks at the challenges of following a gluten-free diet (GFD) for people with celiac disease, which is currently the only treatment available. Researchers found that while the GFD helps heal the gut, it can lead to nutritional deficiencies and is hard to stick to due to factors like cost and taste. To improve adherence and quality of life for patients, the study suggests developing better gluten-free products and exploring new treatments beyond the diet. Who this helps: This helps patients with celiac disease and gluten-related disorders.

Plain English
This study explored how a specific care approach for patients with severe traumatic brain injury (sTBI) affects their survival and recovery, particularly in hospitals that do not monitor the pressure in the skull. The findings showed that patients treated under the Imaging and Clinical Examination (ICE) protocol had a lower death rate of 25% compared to 36% for those treated without a protocol, and better recovery scores (4.7 compared to 3.6). This is important because it suggests that following a structured treatment plan can significantly improve outcomes for patients with sTBI. Who this helps: Patients with severe traumatic brain injury and their healthcare providers.

Plain English
This study looked at patients with Autoimmune Polyglandular Syndrome (APS) type 4 to better understand their experiences and characteristics. Researchers analyzed the medical records of 111 patients, finding that the average age of onset was around 23 years. They discovered that type I diabetes was a major indicator, present in 78% of patients, and that 5% of women experienced early ovarian failure, highlighting the need for awareness of these complications. Who this helps: This research benefits patients and doctors, particularly those working with individuals affected by autoimmune disorders.

Plain English
This study looked at how using a specific treatment protocol called CREVICE helps people with severe traumatic brain injuries (sTBI) recover better compared to no protocol or an older treatment approach. The researchers found that adopting the CREVICE protocol led to a 36% reduction in deaths and improved recovery scores at six months. This matters because better recovery means patients can regain more of their independence and quality of life after a serious injury. Who this helps: This helps patients with severe traumatic brain injuries and the doctors treating them.

Plain English
This study looked at a new treatment called VERVE-101, which uses a technique called CRISPR to permanently change DNA in order to reduce "bad" cholesterol levels. In experiments with monkeys, the treatment was found to lower a protein linked to cholesterol by 83% and the cholesterol levels themselves by 69% after about 476 days. The treatment was safe, showing only temporary mild side effects, and it did not affect reproductive cells in a way that would pass changes to future generations. Who this helps: This benefits patients with high cholesterol, especially those with genetic conditions like familial hypercholesterolemia.

Plain English
This study focused on a new way to deliver a CRISPR therapy to the liver using special nanoparticles that don't rely on a common receptor that some patients lack. The researchers found that by modifying these nanoparticles, they could increase liver editing from 5% to 61% in certain monkeys, and this treatment led to a significant decrease in a specific protein related to cholesterol levels, achieving reductions of up to 89% six months later. This matters because it provides a potential treatment option for patients who cannot use traditional methods due to their genetic conditions. Who this helps: Patients with homozygous familial hypercholesterolemia and other liver-related disorders.

Plain English
Researchers used a gene-editing tool called CRISPR to permanently disable a gene in monkeys' livers that controls cholesterol production, delivering it through tiny fat particles injected into the bloodstream. After a single injection, the monkeys' cholesterol dropped by about 60% and stayed low for at least 8 months without any additional treatment. This proves that gene editing could offer heart disease patients a one-time treatment instead of taking cholesterol drugs for life.

Plain English
This study developed a management guide called the CREVICE Protocol for treating severe traumatic brain injuries (sTBI) when monitoring of intracranial pressure (ICP) isn’t possible. A group of 43 experts created this algorithm to improve care by providing clear steps to identify and treat suspected high pressure inside the skull, addressing 11 key treatment issues based on expert opinions and existing research. This is important because it fills a gap in care for patients in places where resources for monitoring ICP are limited, helping to ensure better treatment outcomes. Who this helps: Patients with severe traumatic brain injuries in resource-limited settings.

Plain English
This study looked at genetic changes in patients with advanced breast cancer to see how they affect the effectiveness of drugs that block estrogen receptors. Researchers found that 10% of over 900 patients had mutations, with the most common one being D538G, present in 36% of affected patients. Certain mutations, particularly Y537S, made the cancer less responsive to the drug fulvestrant, while potentially more effective drugs like AZD9496 could be better options for these patients. Who this helps: This benefits patients with specific breast cancer mutations and their doctors by guiding more effective treatment options.

Plain English
This study examined how tumor cells interact with their surrounding environment, using a method called RNA sequencing to identify specific markers in both tumor and surrounding (stroma) cells in cancer models. Researchers analyzed 79 models and found that mouse stroma can be grouped into distinct types, indicating they respond differently regardless of the tumor type. This research could lead to better identification of cancer subtypes, like using MMP12 as a marker for triple-negative breast cancer, which is crucial for improving treatment strategies. Who this helps: Patients with various types of cancer, particularly those with triple-negative breast cancer.

Plain English
This study focused on a new oral drug called AZD9496, which blocks estrogen receptors in breast cancer cells that are fueled by estrogen. Researchers found that AZD9496 effectively reduced tumor growth even at low doses, specifically showing significant shrinkage in certain cancer models. Combining AZD9496 with other treatments also improved results, suggesting it could be a powerful option for patients with estrogen-driven breast cancer. Who this helps: This benefits patients with ER-positive breast cancer, particularly those having difficulty with current treatments.

Plain English
This study looked at how well different drug combinations work in treating breast cancer that no longer responds to standard hormone therapy due to changes in the estrogen receptor. Researchers found that when the drug fulvestrant was combined with other treatments like JQ1 or vorinostat, tumors shrank by 41% and 22%, respectively. The combination of fulvestrant with other treatments also helped reduce cancer spread to the lungs, which is important for improving patient outcomes. Who this helps: This helps breast cancer patients whose tumors have become resistant to hormone therapy, especially those with specific mutations in the estrogen receptor.

Plain English
This study examined how breast cancer cells that are positive for estrogen receptor (ER+) resist treatment with a drug called everolimus, often used to target certain cancer pathways. The researchers found that a gene called MYC drives this resistance, showing that stopping MYC can make the cancer cells respond better to everolimus again. They discovered that using a drug to block the protein that helps activate MYC, combined with everolimus, significantly reduced tumor growth in cell models. Who this helps: This research helps patients with ER+ breast cancer by providing new potential treatment strategies to overcome drug resistance.

Plain English
This study focused on a new antibody called MEDI-5304, which targets a part of cancer biology known as the hedgehog pathway. Researchers found that MEDI-5304 effectively blocked specific signals in cancer cells that lead to tumor growth, especially in a model of colon cancer, providing a strong anti-tumor effect on its own and enhancing the effectiveness of another cancer drug called carboplatin. However, it did not affect cancer stem cells in pancreatic cancer models. Who this helps: This benefits patients with tumors that have high levels of certain hedgehog proteins, particularly those with colorectal cancer.

Plain English
This research compared two drugs, ML858 and bortezomib, which both target a part of cells called the proteasome that helps control protein levels. The study found that while ML858 binds permanently to the proteasome, bortezomib only binds temporarily, making it more effective over the long term in treating tumors. Specifically, ML858 didn’t keep its effects strong enough to be useful for cancer types that respond to bortezomib, meaning ML858 may need more study before it can be considered a viable treatment option. Who this helps: This helps patients with cancer who are currently treated with bortezomib.